Published in Clujul Med on January 28, 2015
Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2007) 22.81
Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2008) 15.35
G protein pathways. Science (2002) 5.29
More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail (2001) 4.29
Clinical epidemiology of heart failure. Heart (2007) 4.11
Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun (1998) 4.08
Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J (1999) 3.38
Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. Am J Public Health (1994) 3.10
A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene (1993) 2.59
Rehospitalization for heart failure: predict or prevent? Circulation (2012) 2.36
Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol (2006) 2.29
Electrophysiological differentiation of oxytocin- and vasopressin-secreting neurones. Proc R Soc Lond B Biol Sci (1977) 2.24
The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res (2005) 2.24
Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res (2002) 2.15
The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept (2001) 2.07
Down-regulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol (2006) 2.02
Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem (2004) 1.91
Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res (2007) 1.74
Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept (2005) 1.68
Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation (2003) 1.66
Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept (2004) 1.58
Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci U S A (2004) 1.58
Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim Biophys Acta (1999) 1.56
Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem (2000) 1.54
Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J Neurochem (2001) 1.51
Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta (2001) 1.48
Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim Biophys Acta (2000) 1.42
[(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol (2001) 1.40
Apelin has in vivo inotropic effects on normal and failing hearts. Circulation (2004) 1.37
Apelin signalling: a promising pathway from cloning to pharmacology. Cell Signal (2005) 1.31
Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun (2003) 1.19
The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol (2008) 1.18
Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail (2006) 1.12
The apelin receptor is coupled to Gi1 or Gi2 protein and is differentially desensitized by apelin fragments. J Biol Chem (2006) 1.12
Hospitalization for congestive heart failure: United States, 2000-2010. NCHS Data Brief (2012) 1.07
Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J (2011) 1.06
Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues. J Am Heart Assoc (2013) 1.05
The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br J Pharmacol (2013) 0.98
Apelin increases cardiac contractility via protein kinase Cε- and extracellular signal-regulated kinase-dependent mechanisms. PLoS One (2014) 0.97
Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol (1993) 0.96
Apelin is a positive regulator of ACE2 in failing hearts. J Clin Invest (2013) 0.95
Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol (2006) 0.94
Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur J Heart Fail (2006) 0.89
Apelin and its receptor APJ in cardiovascular diseases. Clin Chim Acta (2013) 0.88
Cardioprotective effects of adipokine apelin on myocardial infarction. Heart Vessels (2013) 0.87
Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br J Pharmacol (2010) 0.87
Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J Mol Cell Cardiol (2013) 0.87
Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ J (2011) 0.86
Myocardial apelin production is reduced in humans with left ventricular systolic dysfunction. J Card Fail (2010) 0.82
Transition from metabolic adaptation to maladaptation of the heart in obesity: role of apelin. Int J Obes (Lond) (2014) 0.81
Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. Regul Pept (2007) 0.81
Effects of structural analogues of apelin-12 in acute myocardial infarction in rats. J Pharmacol Pharmacother (2013) 0.80
Effect of apelin on the cardiac hemodynamics in hypertensive rats with heart failure. Int J Mol Med (2014) 0.79
Effects of acute intravenous infusion of apelin on left ventricular function in dogs with advanced heart failure. J Card Fail (2013) 0.79
[Contribution of apelin to water balance, blood glucose control, and cardiovascular functions]. Ann Endocrinol (Paris) (2010) 0.76
New ESC heart failure guidelines with South African expert comment. Cardiovasc J Afr (2012) 0.76